UTAH MEDICAL PRODUCTS INC (UTMD)
Health Care · Medical device manufacturing and specialty instrumentation · NASDAQ
Utah Medical Products designs and manufactures specialized medical devices focused on patient safety in critical care, neonatal intensive care, and women's health.
What UTAH MEDICAL PRODUCTS INC does
Utah Medical Products, Inc. (UTMD) designs, manufactures, and markets differentiated medical devices for critical care settings, particularly the neonatal intensive care unit (NICU), labor and delivery (L&D) departments, and women's health centers. The company sells directly to hospitals and physician offices domestically and through an international network of approximately 200 distributors outside the U.S., with manufacturing facilities in the United States, Ireland, United Kingdom, and Australia. UTMD emphasizes safety-focused innovations that improve patient outcomes and reduce procedure costs, leveraging core competencies in electronics, software, mechanical assembly, instrumentation, and plastics processing.
Themes: ["Women's health / obstetrics","Neonatal intensive care","Patient safety devices","Medical device manufacturing","Critical care equipment"]
Fundamentals
- Price$68.38 as of 2026-07-09 close
- Market cap$211M as of 2026-07-10
- 1-year return+19.4% as of 2026-07-09 close
- P/E19.49 as of 2026-07-10
- Net margin+28.9% as of 2026-07-10
- Gross margin+57.9% as of 2026-07-10
- ROE+9.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-4.4% as of 2026-07-10
- Revenue CAGR (3y)-9.7% SEC XBRL
- Beta0.36 as of 2026-07-10
Dividend: yield +1.8%; pays a dividend.
Key risks (from latest filing)
["Revenue declined 4.43% year-over-year despite profitability, indicating potential market headwinds or product demand pressure in core clinical areas","Significant reliance on international distribution network (approximately 200 overseas distributors) exposed to foreign currency fluctuations and geopolitical risks, as evidenced by accumulated foreign currency translation losses of $9.9 million","Product portfolio concentration risk, with 57% of 2025 sales derived from only four historical acquisitions (Columbia Medical, Gesco neonatal line, Abcorp, and Femcare), creating vulnerability if any major acquired product line underperforms"]
Competitors & peers
- CooperSurgical Inc.
- Medtronic plc
- GE Healthcare
- Philips Healthcare
- Stryker Corporation
- Siemens Healthineers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.